Annual report pursuant to Section 13 and 15(d)

Segments

v2.4.0.8
Segments
12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Segments
Segments
We currently manage our operations in two reportable segments: pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment, which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain and Brazil. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the years ended December 31,
(In thousands)
2013
 
2012
 
2011
Product revenues:
 
 
 
 
 
Pharmaceuticals
$
68,161

 
$
45,295

 
$
27,844

Diagnostics

 

 

Corporate

 

 

 
$
68,161

 
$
45,295

 
$
27,844

Revenue from services:
 
 
 
 
 
Pharmaceuticals
$

 
$

 
$

Diagnostics
10,833

 
395

 

Corporate
825

 
1,354

 
135

 
$
11,658

 
$
1,749

 
$
135

Revenue from transfer of intellectual property:
 
 
 
 
 
Pharmaceuticals
$
15,160

 
$

 
$

Diagnostics
1,551

 

 

Corporate

 

 

 
$
16,711

 
$

 
$

Operating loss from continuing operations:
 
 
 
 
 
Pharmaceuticals
$
(29,809
)
 
$
(6,797
)
 
$
(3,668
)
Diagnostics
(22,199
)
 
(14,259
)
 
(3,984
)
Corporate
(24,473
)
 
(15,628
)
 
(15,537
)
Less: Operating loss attributable to noncontrolling interests
(3,151
)
 
(585
)
 

 
$
(79,632
)
 
$
(37,269
)
 
$
(23,189
)
Depreciation and amortization:
 
 
 
 
 
Pharmaceuticals
$
8,234

 
$
6,367

 
$
2,804

Diagnostics
6,833

 
3,614

 
856

Corporate
149

 
179

 
170

 
$
15,216

 
$
10,160

 
$
3,830

Net loss from investment in investees:
 
 
 
 
 
Pharmaceuticals
(11,456
)
 
(2,062
)
 
(1,589
)
Diagnostics

 

 

Corporate

 

 

 
$
(11,456
)
 
$
(2,062
)
 
$
(1,589
)
Revenues:
 
 
 
 
 
U.S.
$
28,369

 
$
1,749

 
$
135

Chile
31,650

 
26,514

 
21,466

Spain
18,800

 
6,124

 

Israel
13,252

 
7,655

 

Mexico
4,459

 
5,002

 
6,378

 
$
96,530

 
$
47,044

 
$
27,979

(In thousands)
December 31,
2013
 
December 31,
2012
Assets:
 
 
 
Pharmaceuticals
$
1,065,033

 
$
142,299

Diagnostics
116,944

 
112,422

Corporate
209,539

 
35,109

 
$
1,391,516

 
$
289,830

Goodwill:
 
 
 
Pharmaceuticals
$
175,408

 
$
32,844

Diagnostics
50,965

 
47,606

Corporate

 

 
$
226,373

 
$
80,450


During the years ended December 31, 2013 and 2012, no customer represented more than 10% of our total revenue. During the year ended December 31, 2011, one customer represented 17% of our product revenue. As of December 31, 2013 and 2012, no customer represented more than 10% of our accounts receivable balance.